Author

P. Schmassmann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cell type annotation· 3 Research Focus:cell-cell communication· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Organism:mouse· 2

Frequent Co-Authors

M.-F. Ritz· 5 shared S. Hogan· 5 shared T. Shekarian· 5 shared G. Hutter· 4 shared T. A. Martins· 4 shared D. Kaymak· 3 shared J. Roux· 3 shared A. Buck· 2 shared

Activity by Year

2022-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

M.-F. Ritz

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker

T. A. Martins, N. Tatari, D. Kaymak, S. Hogan, E. M. Bartoszek, R. Wieboldt, M.-F. Ritz, A. Buck, M. McDaid, A. Gerber, A. Beshirova, M. M. Etter, A. Heider, T. Shekarian, H. Mohamed, , G. Hutter

This paper develops a CAR T cell therapy that secretes a CD47 blocker to enhance anti-EGFRvIII efficacy against glioblastoma by modulating the tumor microenvironment.

bioRxiv · Aug 31, 2023Cancer Biology

Multidimensional analysis of matched primary and recurrent glioblastoma identifies Fcgamma receptors upregulation on microglia as a contributor of tumor recurrence.

T. Shekarian, S. Hogan, T. A. Martins, P. Schmassmann, A. Gerber, J. Roux, D. Kaymak, C. Durano, B. Burger, M. Matter, M.-F. Ritz, G. A. Hutter

This study identifies Fcgamma receptor upregulation on activated microglia in recurrent glioblastoma as a factor associated with shorter time-to-relapse.

bioRxiv · Apr 21, 2023 · PreprintCancer Biology

The Siglec-sialic acid-axis is a target for innate immunotherapy of glioblastoma

P. Schmassmann, J. Roux, A. Buck, N. Tatari, S. Hogan, J. Wang, S. Lee, B. Snijder, T. A. Martins, M.-F. Ritz, T. Shekarian, D. Kaymak, M. McDaid, M. Weller, T. Weiss, , G. Hutter

This study identifies the Siglec-sialic acid-axis as a target for innate immunotherapy in glioblastoma, showing that blocking Siglec-E enhances phagocytosis and T cell priming, leading to delayed tumor growth and prolonged survival.

bioRxiv · Nov 7, 2022Cancer Biology

Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation

P. Schmassmann, J. Roux, S. Dettling, S. Hogan, T. Shekarian, T. A. Martins, M.-F. Ritz, S. Herter, M. Bacac, G. Hutter

The paper uses single-cell RNA sequencing to analyze regional differences in tumor-infiltrating leukocytes in GBM, revealing distinct transcriptional profiles and impaired activation states.

bioRxiv · Jun 17, 2022 · PreprintCancer Biology

Immunotherapy of glioblastoma explants induces interferon-γ responses and immune cell rearrangements in tumor center, but not periphery

T. Shekarian, C. Zinner, E. Bartoszek, W. Duchemin, A. T. Wachnowicz, S. Hogan, M. M. Etter, J. Flammer, C. Paganetti, T. Martins, P. Schmassmann, S. Zanganeh, F. LeGoff, M. G. Muraro, M.-F. Ritz, , G. Hutter

bioRxiv · Jan 19, 2022Cancer Biology